Core Viewpoint - Meizhong Jiahe Medical Technology Development Group has been approved to enter the "Hong Kong-Macao Drug and Medical Device Access" designated medical institution list, positioning itself as a key beneficiary of the policy and providing clear growth opportunities for investors [1][3]. Group 1: Company Developments - The approval allows Guangzhou Taihe Tumor Hospital to import and use urgently needed drugs and advanced medical devices that are already listed in Hong Kong and Macao but not yet approved in mainland China [1]. - The hospital can now introduce innovative drugs and medical devices in the oncology field, enhancing its competitive advantage and broadening its business scope [1][2]. Group 2: Industry Implications - The "Hong Kong-Macao Drug and Medical Device Access" initiative aims to improve the quality of medical services and align domestic treatments with international standards, particularly in oncology [2][3]. - The initiative is expected to reduce the treatment time gap between mainland China and international markets, particularly for diseases like breast cancer and lung cancer, thereby enhancing patient treatment options [2]. - The increased accessibility of cross-border medical resources will likely attract more patients to hospitals with such capabilities, creating a "regional treatment center" effect and increasing overall service intensity [2][3].

Core Viewpoint - Meizhong Jiahe (02453) has received approval for its subsidiary, Guangzhou Taihe Oncology Hospital, to enter the "Hong Kong-Macao Drug and Medical Device Access" designated medical institution list, enhancing its competitive advantage in the oncology field [2][4]. Group 1: Company Developments - Meizhong Jiahe's stock price increased by 8.67%, reaching HKD 2.13, with a trading volume of HKD 664,600 [2][4]. - The approval allows the hospital to import and use urgently needed drugs and advanced medical devices that are already listed in Hong Kong and Macao but not yet approved in mainland China [2][4]. - This qualification positions the company as a specialized oncology medical institution with the capability to introduce innovative drugs and devices, thereby broadening its business scope and creating a differentiated competitive advantage in the market [2][4]. Group 2: Industry Context - The "Hong Kong-Macao Drug and Medical Device Access" initiative is a key implementation measure of the "Guangdong-Hong Kong-Macao Greater Bay Area Drug and Medical Device Regulatory Innovation Development Work Plan" [2][4]. - The initiative aims to facilitate the use of clinically necessary drugs and advanced medical devices in designated institutions within the Greater Bay Area, enhancing healthcare access for patients [2][4].

Core Viewpoint - Meizhong Jiahe (02453) has seen a significant stock price increase of 6.12%, reaching HKD 2.08, following the announcement of its subsidiary Guangzhou Taihe Oncology Hospital being approved to enter the "Hong Kong-Macao Drug and Medical Device Access" list, enhancing its competitive edge in the oncology sector [1] Group 1 - The approval from the Guangdong Provincial Health Commission and the Guangdong Provincial Drug Administration allows the hospital to import and use urgently needed drugs and advanced medical devices that are already listed in Hong Kong and Macao but not yet approved in mainland China [1] - This qualification positions the company as a specialized oncology medical institution with the capability to utilize innovative drugs and medical devices, thereby broadening its business scope and creating a differentiated competitive advantage in the market [1] - The initiative is part of the core implementation measures of the "Guangdong-Hong Kong-Macao Greater Bay Area Drug and Medical Device Regulatory Innovation Development Work Plan," which aims to facilitate the use of clinical urgently needed drugs and advanced medical devices in designated medical institutions [1]

Core Viewpoint - The company, Meizhong Jiahe (02453), announced that its subsidiary, Guangzhou Taihe Oncology Hospital, has been approved to enter the "Hong Kong-Macao Drug and Medical Device Access" designated medical institution list, enhancing its capabilities in oncology treatment and competitive advantage in the market [1] Group 1 - The approval was granted by the Guangdong Provincial Health Commission and the Guangdong Provincial Drug Administration, allowing the hospital to import and use urgently needed drugs and advanced medical devices that are already listed in Hong Kong and Macao but not yet approved in mainland China [1] - This qualification enables the company to be recognized as a professional oncology medical institution with the capability to utilize innovative drugs and medical devices from Hong Kong and Macao, thereby broadening its business scope [1] - The initiative will facilitate deeper integration with Hong Kong and Macao medical resources, enhancing clinical diagnosis and treatment levels, and accelerating alignment with international medical standards [1] Group 2 - The introduction of cutting-edge drugs and medical devices is expected to optimize oncology treatment plans and improve patient service experience and treatment outcomes [1] - The company aims to provide urgently needed medications for more oncology patients, reinforcing its competitive edge in the oncology medical field [1]